Back to the main directory
Company Analysis / Equity
- Volkswagen Management Shake-Up May Be Just What the Doctor Ordered, EUR 221 FVE Unchanged by Morningstar
- Martin Sorrell Steps Down; WPP’s Market Leadership Position Not at Risk; Maintaining GBX 1,500 FVE by Morningstar
- India Strategy - Economy gathers steam… by IDFC Securities
- Entzug der Produktionsbewilligung für einige Arzneimittel by Sphene Capital GmbH
- Raise TP by c26%; Remain Overweight by CI Capital
- Intermarket Pulse: Pakistan Banks: Lower capital gains to drag 1QCY18 results by Intermarket Securities Limited
- CIS Market Daily - April 16, 2018 by Sberbank
- Gj.18-19 beginnt nach Plan – H2/18 wird besser by EQUITS GmbH
- CA T1 : Les Etats-Unis prennent le relais, l'Europe cale - Opinion Achat - Obj. 3,02 € - Potentiel +34,3% by GreenSome Finance
- CHARGEURS. Turnover Q1 2018. A good performance despite the currency effects and comparison bases by MidCap Partners
- Against the cycle, Zurich Insurance is restoring its business to better strength. by Morningstar
- Carr's Group - Recovery continues by Edison Investment Research
- Dauerhafte Rückkehr in die Gewinnzone bestätigt by Sphene Capital GmbH
- Initial View: Presco Plc. FY 17 - Surprise increase in OPEX offset Q4 revenue growth by ARM Securities Limited
- Munich Re is one of the best-quality reinsurers. by Morningstar
- Q1 snap: low provisions and tax drive 5% beat by Atlantic Equities
- Hohes Umsatz- und Ergebniswachstum nach Sonderjahr erwartet, Kursziel unverändert by GBC AG
- Sierra Oncology - Progress with ongoing trials and future plans by Edison Investment Research
- Sabre's evolving technology supports its network, efficient scale, and switching cost advantages. by Morningstar
- Heliad Equity Partners - Strong gains allow further diversification by Edison Investment Research
- Merck's life sciences division should help offset pharmaceutical and liquid crystal headwinds. by Morningstar
- Merck and Bristol Post Strong Data, Reaffirming Immuno Oncology’s Potential and Merck’s Leadership by Morningstar
- Merck and Bristol Post Strong Data, Reaffirming Immuno Oncology’s Potential and Merck’s Leadership by Morningstar
- Daqin’s Strong Preliminary 2017 Result In Line; Raising Our FVE to CNY 9.70 per Share by Morningstar
- Efficiency is the name of the game for Bank of America. by Morningstar